{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06253130",
            "orgStudyIdInfo": {
                "id": "EIK1003-001 (IMP1734-101)"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-509230-19",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "Eikon Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors",
            "officialTitle": "A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-first-in-human-study-of-selective-inhibitor-in-participants-with-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-12-11",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-02-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-01-27",
            "studyFirstSubmitQcDate": "2024-02-02",
            "studyFirstPostDateStruct": {
                "date": "2024-02-12",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Eikon Therapeutics",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Impact Therapeutics, Inc.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study will evaluate the preliminary efficacy of IMP1734 in patients with recurrent advanced/metastatic breast cancer, ovarian cancer and metastatic castrate resistant prostate cancer (mCRPC) with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes.",
            "detailedDescription": "This study will evaluate the safety, tolerability and preliminary efficacy of IMP1734 as monotherapy in patients with recurrent, advanced/metastatic solid tumors. The study consists of 3 parts: Dose escalation, Dose Optimization and Dose expansion.\n\nIn dose escalation (Part1 ), the study will identify the maximum tolerated dose (MTD) or maximum achievable dose (MAD) in solid tumor.\n\nIn dose optimization (Part 2), the study will further evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of select doses of IMP1734.\n\nIn dose expansion (Part 3) the recommended dose escalation (RDE) of IMP1734 monotherapy will be evaluated in patients with recurrent, advanced/metastatic breast cancer, ovarian cancer and mCRPC with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) gene mutations."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumor"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 70,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1",
                    "type": "EXPERIMENTAL",
                    "description": "IMP1734 monotherapy; oral tablet(s) daily (except for the single-dose period). The maximum trial duration is 3 years after the last participant's first treatment in the trial.",
                    "interventionNames": [
                        "Drug: IMP1734"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "IMP1734",
                    "description": "PARP1 selective inhibitor",
                    "armGroupLabels": [
                        "Cohort 1"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of subjects with adverse events, treatment emergent adverse events or serious adverse events",
                    "description": "Number of subjects reporting adverse events or serious adverse events which include any abnormal clinical events, laboratory assessments outside of normal clinical range, abnormal vital signs observed, and any abnormal ECG parameters",
                    "timeFrame": "Consent to 30 + 7 days post last dose of IMP1734"
                },
                {
                    "measure": "Maxim Tolerated Dose or Recommended Dose for Expansion",
                    "description": "Number of patients that experience a DLT or any toxicity which occurs from the time of the first dose of study drug until the end of cycle 1, which is deemed unrelated to the disease.",
                    "timeFrame": "DLT period is from the first dose of the study drug until the last day of the first cycle"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Pharmacokinetic parameters of IMP1734",
                    "description": "Peak plasma concentration (Cmax)",
                    "timeFrame": "Through study completion, up to 3 years"
                },
                {
                    "measure": "Pharmacokinetic parameters of IMP1734",
                    "description": "Time to peak drug concentration (Tmax)",
                    "timeFrame": "Through study completion, up to 3 years"
                },
                {
                    "measure": "Pharmacokinetic parameters of IMP1734",
                    "description": "Area under the curve (AUC) will be defined",
                    "timeFrame": "Through study completion, up to 3 years"
                },
                {
                    "measure": "Overall Response Rate",
                    "description": "Percentage of participants who have CR/PR per RECIST v1.1,and/or CA125 response per GCIG criteria (ovarian cancer), and/or PSA response per PCWG3 criteria",
                    "timeFrame": "Through study completion, up to 3 years"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Characterization of the pharmacodynamic changes due to IMP1734",
                    "description": "Evaluation of serial pharmacodynamic changes across multiple doses of IMP1734",
                    "timeFrame": "Through study completion, up to 3 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria\n\n* Breast cancer; must have received at least one prior chemotherapy in neoadjuvant/adjuvant/metastatic setting, must have received hormonal therapy if HR+,\n* HGSOC or high grade endometrioid EOC, fallopian tube or primary peritoneal cancer; must have received at least one prior platinum-based chemotherapy for advanced disease\n* mCRPC with ongoing ADT, must have received NHA and up to 1 prior line of taxane chemotherapy\n* Age \u2265 18 years at the time of informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status \u22641\n* Adequate organ function\n* Life expectancy \u2265 12 weeks\n* Should have evaluable disease as defined by RECIST1.1 and/or CA125 or PSA\n* Female subjects of childbearing potential and male subjects must agree to use an effective method of contraception from study entry up to 6 months after the last dose of IMP1734\n* deleterious or suspected deleterious germline or somatic mutations of select HHR genes\n* up to 1 prior line of PARP inhibitor containing treatment\n\nKey Exclusion Criteria:\n\n* Any investigational or approved anti-cancer therapies administered within 28 days/ before the first dose of IMP1734\n* Have received prior PARP1 selective inhibitors\n* Mean resting QTcF \\> 470 ms or QTcF \\< 340 ms\n* Active or untreated central nervous system (CNS) metastases and/or carcinomatous meningitis.\n* Infections\n\n  - An active hepatitis B/C infection\n* Any known predisposition to bleeding\n* Unable to swallow oral medications OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition that might impair the bioavailability",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "89 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Caroline Taromino",
                    "role": "CONTACT",
                    "phone": "(341) 777-0566",
                    "email": "parpitrial@eikontx.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Viola Chen, MD",
                    "affiliation": "Eikon Therapeutics",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Sarah Cannon Research Institute Health One",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80218",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alissa Snow",
                            "role": "CONTACT",
                            "email": "Alissa.Snow@SarahCannon.com"
                        },
                        {
                            "name": "Gerald Falchook, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "Advent Health Research Institute",
                    "status": "RECRUITING",
                    "city": "Celebration",
                    "state": "Florida",
                    "zip": "34747",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Charmaine Garcia",
                            "role": "CONTACT",
                            "email": "charmaine.garcia@adventhealth.com"
                        },
                        {
                            "name": "Sonpavde Guru, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.32529,
                        "lon": -81.53313
                    }
                },
                {
                    "facility": "Sarah Cannon Research Institue Oncology",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Tallia Popwycz",
                            "role": "CONTACT",
                            "email": "Tallia.popowycz@scri.com"
                        },
                        {
                            "name": "Benjamin Garmezy, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "START - South Texas Accelerated Research Therapeutics",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jacquelin Cervantes",
                            "role": "CONTACT",
                            "email": "jacquelin.cervantes@startsa.com"
                        },
                        {
                            "name": "Drew Rasco, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "START Mountain Region",
                    "status": "RECRUITING",
                    "city": "West Valley City",
                    "state": "Utah",
                    "zip": "84119",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Marianne Herndon",
                            "role": "CONTACT",
                            "email": "marianne.herndon@startthecure.com"
                        },
                        {
                            "name": "Justin Call, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.69161,
                        "lon": -112.00105
                    }
                },
                {
                    "facility": "Scientia Clinical Research Ltd",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Randwick",
                    "state": "New South Wales",
                    "zip": "2031",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Grace Hwang",
                            "role": "CONTACT",
                            "email": "Grace.hwang@scientiaclinicalresearch.com"
                        },
                        {
                            "name": "Christina Teng",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -33.91439,
                        "lon": 151.24895
                    }
                },
                {
                    "facility": "Mater Cancer Care Centre, Mater Misericordiae Limited",
                    "status": "NOT_YET_RECRUITING",
                    "city": "South Brisbane",
                    "state": "Queensland",
                    "zip": "4101",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Hanumasri Matturi",
                            "role": "CONTACT",
                            "email": "Hanumasri.Matturi@mater.org.au"
                        },
                        {
                            "name": "Catherine Shannon",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -27.48034,
                        "lon": 153.02049
                    }
                },
                {
                    "facility": "Gold Coast Private Hospital",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Southport",
                    "state": "Queensland",
                    "zip": "4125",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Michelle Cestari",
                            "role": "CONTACT"
                        },
                        {
                            "role": "CONTACT",
                            "email": "Michelle.Cestari@healthscope.com.au"
                        },
                        {
                            "name": "Andrea Tazbirkova",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -27.96724,
                        "lon": 153.39796
                    }
                },
                {
                    "facility": "Macquarie University",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Sydney",
                    "state": "Queensland",
                    "zip": "2109",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Jacqui Delahunt Smoleniec",
                            "role": "CONTACT",
                            "email": "jacqui.delahunt@mq.edu.au"
                        },
                        {
                            "name": "Dhanusha Sabanathan",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -33.86785,
                        "lon": 151.20732
                    }
                },
                {
                    "facility": "Princess Alexandra Hospital",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Woolloongabba",
                    "state": "Queensland",
                    "zip": "4102",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Jillian Hung",
                            "role": "CONTACT"
                        },
                        {
                            "role": "CONTACT",
                            "email": "Jillian.Hung@health.qld.gov.au"
                        },
                        {
                            "name": "Wen Xu",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -27.48855,
                        "lon": 153.03655
                    }
                },
                {
                    "facility": "Peninsula and south eastern haematology and oncology group",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Frankston",
                    "state": "Victoria",
                    "zip": "3199",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Henry Gordon",
                            "role": "CONTACT",
                            "email": "hg@paso.com.au"
                        },
                        {
                            "name": "Vinod Ganju",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -38.14458,
                        "lon": 145.12291
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        }
    },
    "hasResults": false
}